摘要
重组人血小板生成素(rhTPO)在临床上广泛用于治疗免疫性血小板减少症、恶性肿瘤化疗后血小板减少症及脓毒症血小板减少症^([1,2,3])等,许多研究证明了其疗效及安全性。近几年,此药物联合免疫抑制剂治疗重型再生障碍性贫血的患者。本文对此方面研究做一综述。
Recombinant human thrombopoietin(rh TPO) is widely applied for clinical treatment of immune thrombocytopenia, thrombocytopenia after chemotherapy of malignant tumor and sepsis thrombocytopenia [1,2,3], many studies have proved its effects and safety. In recent years, the drug combined with immunosuppressive agents is applied for treatment of severe aplastic anemia patients. The article summarizes related research.
出处
《智慧健康》
2017年第24期83-84,共2页
Smart Healthcare
关键词
血小板
贫血
重组
Platelets
Anemia
Recombinant
